Drug intelligence / Profile preview

NWRD02

Development stage: Unknown
Lead developer: Newish Biotechnology
Modality: Spiegelmers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapy Plasmids → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Protein Replacement mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Natural RNA Aptamers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Unmodified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Long Non-coding RNA (lncRNA) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

NWRD02 is a nucleic acid-based vaccine candidate, specifically a DNA vaccine, developed by Newish Biotechnology for the prevention of COVID-19. It is built using the company's proprietary STARi (Super Targeting Activated Response of Immunization) platform, which is designed to overcome the low immunogenicity often associated with traditional DNA vaccines. The STARi technology utilizes a dual-action strategy: it encodes the SARS-CoV-2 spike protein antigen fused with sequences that target the protein to dendritic cells (DCs) via specific receptors, while simultaneously expressing molecular adjuvants that trigger DC maturation and activation. This approach is intended to induce a potent and durable immune response, including both neutralizing antibodies and cytotoxic T-lymphocyte (CTL) activity. NWRD02 is one of four Class 1 new drugs from Newish Biotechnology to receive clinical trial clearance from China's National Medical Products Administration (NMPA).

Other names: SARS-CoV-2 nucleic acid drug (STARi platform)STARi-SARS-CoV-2 vaccineSTARi-SARS-CoV2 vaccineSTARi-SARS-CoV 2 vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on NWRD02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NWRD02.

Explore the full profile